(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Overseeing Individual budgets Successfully- Shipping: The Corridors of Trade and the Coming of Another Period
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Home Mechanization Frameworks for Brilliant Residing
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis
